Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning to rise, according to a survey conducted by Spherix Global Insights.
Also, COVID-19 not only has delayed and impaired the launch of Zeposia — approved in the U.S in March — but also affected the way physicians managed their MS patients and was often the cause of drops in S1P receptor modulators use “over the past three months,” a press release summarizing the report noted.
Results of the online survey, sent to 99 neurologists in the U.S. between July and August, were detailed in the newest quarterly report “RealTime Dynamix: Multiple Sclerosis (US).” The survey looked into trends regarding disease-modifying therapy (DMT) use and future expectations.
Zeposia, developed by Bristol Myers Squibb’s Celgene, is the third oral S1P receptor modulator approved for relapsing forms of MS, following Gilenya and Mayzent (siponimod), both marketed by Novartis.
This type of therapy works by preventing immune cells from leaving the lymph nodes, entering circulation, and reaching the brain and spinal cord, where they can promote further inflammation and nerve cell damage.
Because Zeposia is more selective for certain types of S1P receptors, it is thought to have a better safety profile than Gilenya. According to Bristol Myers Squibb, Zeposia also is currently the only S1P receptor modulator that does not require a genetic test or an observation period for most patients being given the first dose.
Despite its delayed launch in June, Zeposia was prescribed by about 20% of surveyed physicians within its first two months of availability. Consistent with Bristol Myers Squibb’s positioning efforts, neurologists were most willing to prescribe Zeposia to people with relapsing-remitting MS (RRMS), active secondary progressive MS (SPMS), or those transitioning between the two disease forms.
However, the therapy faces substantial competition within the field of relapsing MS, both from other high-efficacy oral DMTs (including S1P receptor modulators) and especially from Ocrevus (ocrelizumab), the report noted.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?